Sugi Predict

Sugi Predict / Targets / LATS2

LATS2

Serine/threonine-protein kinase LATS2 · Q9NRM7 · LATS2 on Sugi Atlas →

6,410 patent compounds predicted against LATS2, 2,854 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL10267456 SCHEMBL10267456 0.59 16/20
SCHEMBL12963842 SCHEMBL12963842 0.64 15/20
SCHEMBL12619526 SCHEMBL12619526 0.62 15/20
SCHEMBL10267527 SCHEMBL10267527 0.67 13/20
SCHEMBL801991 SCHEMBL801991 0.65 13/20
SCHEMBL12657441 SCHEMBL12657441 0.47 13/20
SCHEMBL13300155 SCHEMBL13300155 0.45 13/20
SCHEMBL802011 SCHEMBL802011 0.50 12/20
SCHEMBL2458463 SCHEMBL2458463 0.42 12/20
SCHEMBL9979238 SCHEMBL9979238 0.61 11/20
SCHEMBL12558152 SCHEMBL12558152 0.59 11/20
SCHEMBL12039884 SCHEMBL12039884 0.61 10/20
SCHEMBL9979194 SCHEMBL9979194 0.48 10/20
SCHEMBL12653338 SCHEMBL12653338 0.46 10/20
SCHEMBL3459846 SCHEMBL3459846 0.72 9/20
SCHEMBL7610908 SCHEMBL7610908 0.55 9/20
SCHEMBL9979369 SCHEMBL9979369 0.51 9/20
SCHEMBL13300241 SCHEMBL13300241 0.43 9/20
SCHEMBL7612750 SCHEMBL7612750 0.53 8/20
SCHEMBL7604895 SCHEMBL7604895 0.53 8/20

Clinical trials — most relevant to LATS2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit PHASE2/PHASE3WITHDRAWN
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib PHASE2COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
SCARFREE-001: Verteporfin for Scar Prevention PHASE2NOT_YET_RECRUITING
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI PHASE2COMPLETED
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Temsirolimus as Second-line Therapy in HCC PHASE2UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Glutamine Supplementation in People With Immune Dysregulation EARLY_PHASE1WITHDRAWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Muscle Regrowth During Physical Rehabilitation and Amino Acid Supplementation nanCOMPLETED
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? nanUNKNOWN
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
What is the Impact of TKI on Thyroid Function in CML Patients? nanNOT_YET_RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea nanRECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
Protein Synthesis in the Brain of Patients With Fragile X Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a LATS2 binder may also engage these)

ProteinNameSimilarity
Q7TSJ6 — 0.999 Q7TSJ6 →
A7MBB4 — 0.995 A7MBB4 →
Q6P4S6 — 0.994 Q6P4S6 →
SIK3 Serine/threonine-protein kinase SIK3 0.993 landscape →
Q6NSM8 — 0.993 Q6NSM8 →
SNRK SNF-related serine/threonine-protein kinase 0.993 landscape →
O97775 — 0.992 O97775 →
Q63553 — 0.992 Q63553 →
Q5HZJ0 — 0.992 Q5HZJ0 →
Q9CWL2 — 0.992 Q9CWL2 →
Q9TT90 — 0.992 Q9TT90 →
Q04888 — 0.992 Q04888 →
P21999 — 0.992 P21999 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.992 landscape →
TNIK TRAF2 and NCK-interacting protein kinase 0.992 landscape →
BMP2K BMP-2-inducible protein kinase 0.991 landscape →
Q2EJA0 — 0.991 Q2EJA0 →
O55170 — 0.991 O55170 →
Q3ULB5 — 0.991 Q3ULB5 →
MAP4K4 Mitogen-activated protein kinase kinase kinase kinase 4 0.991 landscape →
Q9Z1N7 — 0.991 Q9Z1N7 →
O70441 — 0.991 O70441 →
Q8MIK0 — 0.991 Q8MIK0 →
Q6QT55 — 0.991 Q6QT55 →
MINK1 Misshapen-like kinase 1 0.991 landscape →
Q3UTQ8 — 0.991 Q3UTQ8 →
P01103 — 0.991 P01103 →
Q9H329 — 0.990 Q9H329 →
Q9GKL7 — 0.990 Q9GKL7 →
Q71QF9 — 0.990 Q71QF9 →